



To the OMX  
Announcement No. 42-07 / Copenhagen 6 December 2007

TopoTarget A/S  
Symbion  
Fruebjergvej 3  
DK 2100 Copenhagen  
Denmark  
Tel: +45 39 17 83 92  
Fax: +45 39 17 94 92  
CVR-nr: 25695771

## Report pursuant to the Danish Securities Trading Act, Section 28a

[www.topotarget.com](http://www.topotarget.com)

**Copenhagen – 6 December 2007** – Pursuant to the Danish Securities Trading Act, Section 28a TopoTarget A/S (OMX: TOPO) is obliged to report on transactions by members of its senior management and their related parties in shares issued by TopoTarget A/S and related securities.

Name	Leif Hamø
Reason	CFO
Issuer and ISIN code	TopoTarget A/S, DK0060086072
Transaction	Purchase
Trade date	27 November 2007
Market	Copenhagen Stock Exchange
Number	10,000
Market value in DKK	209,000

### TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

### Background information

#### About TopoTarget

TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the UK, Germany, Switzerland and the US, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and eight drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ is TopoTarget's first product on the market. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

